Moreover, by assessing an independent data set of 166 ROS1-rearranged NSCLCs detected by FoundationOne CDx test (Foundation Medicine), these authors only identified one case with concomitant driver mutation in EGFR. Thus, further studies are necessary to evaluate the possible impact of ROS1 co-alterations on the response to TKIs in EGFRM+ NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.